Replies to post #101450 on Biotech Values

[DewDiligence]

Craig Wheeler answered an analyst question regarding your above comment on the FDA approval conference call. If I remember correctly, he said the product has a long inventory life and didn't believe there would be any significant write-down on the inventory. Dew, can you confirm my above comment?

Yes, Wheeler did say that inventory write-offs from shelf-life expiration were not a material item.

Preparing for the launch of a product whose launch date is unknown is a tradeoff between producing too little inventory to meet initial demand and producing so much inventory that a significant amount expires prior to launch. NVS/MNTA seem to have found a reasonable middle ground.